Resumen

Background: Patients with acute leukemia can express aberrant markers, defined as antigens that are normally restricted to a different lineage. The reported significance and frequency of these markers is inconclusive. We assessed the frequency and impact of aberrant markers in patients with acute leukemia in a referral institution in Mexico City. Methods: We included 433 patients, diagnosed and treated between 2005 and 2015 in our institution. Results: Aberrant markers were expressed in 128 patients (29.6%); CD13 and CD33 were the most frequent aberrant markers in patients with acute lymphoblastic leukemia, while CD7 and CD19 were the most frequent in patients with acute myeloid leukemia. In the univariate analysis, the group with aberrant markers had a lower disease free survival when compared with the aberrant-free group (8 vs. 13 months) (p = 0.03). Aberrant expression of CD10, CD20, and CD33 correlated with a worse outcome in a statistically significant manner. In the multivariate analysis, male gender, lymphoid lineage, secondary leukemia, high risk at diagnosis, and the presence of aberrant markers had a significantly negative impact on disease-free survival. Conclusion: The use of more aggressive treatment strategies could be considered in patients with acute leukemia and an aberrant expression of CD10, CD20, and CD33.

Palabras clave: Aberrant marker acute leukemia acute lymphoblastic leukemia acute myeloid leukemia flow cytometry.

2017-02-02   |   496 visitas   |   Evalua este artículo 0 valoraciones

Vol. 68 Núm.6. Noviembre-Diciembre 2016 Pags. 305-313 Rev Invest Clin 2016; 68(6)